|
2021 Conference Publication A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)Mollee, Peter, Reynolds, John, Janowski, Wojciech, Quach, Hang, Campbell, Philip, Gibbs, Simon D., Lee, Sophie, D'Rozario, James, Taylor, Kerry, Cochrane, Tara, Wallington-Beddoe, Craig Thomas, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian H., Weston, Helen, Ho, P. Joy, Horvath, Noemi, Yuen, Flora and Spencer, Andrew (2021). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-152500 |
|
2021 Conference Publication Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Li Chai, Khai, Wellard, Cameron, Moore, Elizabeth M., Augustson, Bradley, Bapat, Akshay, Blacklock, Hilary Anne, Cooke, Rachel Elizabeth, Forsyth, Cecily, Hamad, Nada, Harrison, Simon J., Ho, Phobe Joy, Hocking, Jay, Kerridge, Ian H., King, Tracy, McCaughan, Georgia J., Mollee, Peter, Morrissey, Orla, Murphy, Nicholas E., Quach, Hand, Tan, Xuan Ni, Wong, Kimberly, Spencer, Andrew, Wood, Erica M. and McQuilten, Zoe (2021). Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-147622 |
|
2021 Journal Article Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma AllianceBoyle, Stephen, Tobin, Joshua W. D., Perram, Jacinta, Hamad, Nada, Gullapalli, Veena, Barraclough, Allison, Singaraveloo, Lydia, Han, Min-Hi, Blennerhassett, Richard, Nelson, Niles, Johnston, Anna M., Talaulikar, Dipti, Karpe, Krishna, Bhattacharyya, Abir, Cheah, Chan Yoon, Subramoniapillai, Elango, Bokhari, Waqas, Lee, Cindy, Hawkes, Eliza A., Jabbour, Andrew, Strasser, Simone, Chadban, Steven J., Brown, Christina, Mollee, Peter and Hapgood, Greg (2021). Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma Alliance. HemaSphere, 5 (11) e648, 1-8. doi: 10.1097/hs9.0000000000000648 |
|
2021 Journal Article Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaCreeper, Katherine, Augustson, Bradley, Kusel, Kieran, Fulham, Michael J., Ho, Joy, Quach, Hang, Mollee, Peter, Weber, Nicholas, Talaulikar, Dipti, Johnston, Anna, Murphy, Nick, Joshua, Douglas, Ward, Christopher, Ling, Silvia, Gibson, John, Szer, Jeff, Harrison, Simon, Zannettino, Andrew, Jaksic, Wilfrid, Lee, Cindy, Spencer, Andrew, Kalff, Anna, Szabo, Ferenc, Romeril, Ken, Chan, Henry, Gibbs, Simon, Horvath, Noemi and Prince, H. Miles (2021). Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 51 (10), 1707-1712. doi: 10.1111/imj.15457 |
|
2021 Journal Article Daratumumab-based treatment for immunoglobulin light-chain amyloidosisKastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon, Mollee, Peter, Venner, Christopher P., Lu, Jin, Schönland, Stefan, Gatt, Moshe E., Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Huart, Antoine, Dimopoulos, Meletios A., Bhutani, Divaya, Waxman, Adam J., Goodman, Stacey A., Zonder, Jeffrey A. ... Comenzo, Raymond L. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. New England Journal of Medicine, 385 (1), 46-58. doi: 10.1056/NEJMoa2028631 |
|
2021 Journal Article Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based inductionBoyle, Stephen, Wellard, Cameron, Moore, Elizabeth M., Blacklock, Hilary, Harrison, Simon J., Ho, Phoebe Joy, Hocking, Jay, McQuilten, Zoe K., Quach, Hang, Spearing, Ruth, Wood, Erica M., Spencer, Andrew and Mollee, Peter (2021). Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. European Journal of Haematology, 107 (4) ejh.13677, 497-499. doi: 10.1111/ejh.13677 |
|
2021 Journal Article The myeloma landscape in Australia and New Zealand: the first 8 years of the Myeloma and Related Diseases Registry (MRDR)Bergin, Krystal, Wellard, Cameron, Moore, Elizabeth, McQuilten, Zoe, Blacklock, Hilary, Harrison, Simon J., Ho, P. Joy, King, Tracy, Quach, Hang, Mollee, Peter, Walker, Patricia, Wood, Erica and Spencer, Andrew (2021). The myeloma landscape in Australia and New Zealand: the first 8 years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 21 (6), e510-e520. doi: 10.1016/j.clml.2021.01.016 |
|
2021 Conference Publication A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, SealandQuach, Hang, Lasica, Masa, Routledge, David, Kalff, Anna, Lim, Andrew, Low, Michael, Estell, Jane A., Sidiqi, M. Hasib, Campbell, Philip, Eek, Richard Wilhelm, Lai, Hock C., McCaughan, Georgia J., D'Rozario, James, Browlett, Peter, Rajagopal, Rajeev, Heenan, Jessica, Murphy, Nicholas E., Renwick, William, Huan, Georgina and Mollee, Peter (2021). A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand. Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 04-08, 2021. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2021.39.15_suppl.TPS8055 |
|
2021 Journal Article Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)Bergin, Krystal, Wellard, Cameron, Augustson, Bradley, Cooke, Rachel, Blacklock, Hilary, Harrison, Simon J., Ho, Joy, King, Tracy, Quach, Hang, Mollee, Peter, Walker, Patricia, Moore, Elizabeth, McQuilten, Zoe, Wood, Erica, Spencer, Andrew and on behalf of the Australian and New Zealand Myeloma and Related Diseases Registry (2021). Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 56 (10), 2533-2543. doi: 10.1038/s41409-021-01308-8 |
|
2021 Journal Article The Clinical Impact of Proteomics in Amyloid TypingHill, Michelle M., Dasari, Surendra, Mollee, Peter, Merlini, Giampaolo, Costello, Catherine E., Hazenberg, Bouke P.C., Grogan, Martha, Dispenzieri, Angela, Gertz, Morie A., Kourelis, Taxiarchis and McPhail, Ellen D. (2021). The Clinical Impact of Proteomics in Amyloid Typing. Mayo Clinic Proceedings, 96 (5), 1122-1127. doi: 10.1016/j.mayocp.2020.12.002 |
|
2021 Journal Article Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel findingMar, Ethan, Taylor, Kerry and Mollee, Peter (2021). Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding. BMJ Case Reports, 14 (4) e240631, 1-1. doi: 10.1136/bcr-2020-240631 |
|
2021 Journal Article Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocolUllman, Amanda J., August, Deanne, Kleidon, Tricia, Walker, Rachel, Marsh, Nicole M., Bulmer, Andrew, Pearch, Benjamin, Runnegar, Naomi, Schults, Jessica A., Leema, Joanne, Lee-Archer, Paul, Biles, Cathy, Southam, Katrina, Gibson, Victoria, Byrnes, Joshua, Ware, Robert S., Chopra, Vineet, Coulthard, Alan, Mollee, Peter, Rickard, Claire M. and Harris, Patrick N. A. (2021). Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol. BMJ Open, 11 (4) e042475, 1-7. doi: 10.1136/bmjopen-2020-042475 |
|
2021 Journal Article Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w)Burgess, M., Chen, Y. C.E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2021). Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w). Oncogene, 40 (6), 1203-1203. doi: 10.1038/s41388-020-01619-y |
|
2021 Journal Article SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patientsChen, Yu-Chen Enya, Burgess, Melinda, Mapp, Sally, Mollee, Peter, Gill, Devinder, Blumenthal, Antje and Saunders, Nicholas A. (2021). SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients. Frontiers in Immunology, 11 610523, 1-12. doi: 10.3389/fimmu.2020.610523 |
|
2021 Journal Article Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trialPerrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, van Rampelbergh, Rian, Uhlar, Clarissa M., Wang, Jianping, Kobos, Rachel, Gries, Katharine S., Fastenau, John and Weisel, Katja (2021). Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial. Journal of Clinical Oncology, 39 (3), 227-237. doi: 10.1200/JCO.20.01370 |
|
2021 Journal Article A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaTobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866 |
|
2021 Journal Article Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein ReportingSmith, Joel D, Wijeratne, Nilika, Schneider, Hans G, de Malmanche, Theo, Hissaria, Pravin, Toit, Stephen Du, Chiu, Weldon, Boyder, Conchita, Morison, Ian M, Tseng, Anfernee, Glegg, Kaye, Wienholt, Louise, Mollee, Peter and on behalf of the AACB/RCPA Monoclonal Gammopathy Working Party (2021). Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting. Clinical Biochemist Reviews, 42 (1), 11-16. doi: 10.33176/AACB-21-00001 |
|
2021 Journal Article The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemiaMurali, Aarya, Cross, Donna and Mollee, Peter (2021). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia. Blood Cancer Journal, 11 (1) 6, 6. doi: 10.1038/s41408-020-00401-3 |
|
2021 Journal Article The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograftRees, Matthew J., Mollee, Peter, Ng, Jun Yen, Murton, Alex, Gonsalves, Jose Filipe, Panigrahi, Ashish, Beer, Hayley, Loh, Joanna, Nguyen, Philip, Hunt, Sam, Jina, Hayden, Wayte, Rebecca, Sutrave, Gaurav, Tan, Jocelyn, Abeyakoon, Chathuri, Chee, Ashlyn, Augustson, Bradley, Kalro, Akash, Lee, Cindy, Agrawal, Shivam, Churilov, Leonid, Chua, Chong Chyn, Lim, Andrew Boon Ming, Zantomio, Daniela and Grigg, Andrew (2021). The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. Bone Marrow Transplantation, 56 (9), 2152-2159. doi: 10.1038/s41409-021-01300-2 |
|
2020 Journal Article Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devicesEllis, Marc L., Okano, Satomi, McCann, Andrew, McDowall, Angela, Van Kuilenburg, Rosita, McCarthy, Alexandra L., Joubert, Warren, Harper, John, Jones, Mark and Mollee, Peter (2020). Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Internal Medicine Journal, 50 (12), 1475-1482. doi: 10.1111/imj.14780 |
